These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. Private Securities Litigation Reform Act of 1995. This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
For more information, visit and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.įorward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. For more information visit įor more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Usage of the new company logo and brand is effective upon completion of the spinoff in the first half of 2021. “Organon will set a new direction for the future of women’s health bringing new hope and treatments worldwide while also focusing on its important biosimilars and legacy brands.”
“Recognizing that Organon has a strong reputation among healthcare providers, the name offers the company a solid foundation to pursue global leadership and sustainable growth in women’s health,” said Kevin Ali, who has been named CEO of Organon. Organon will also focus on its important biosimilars business, focusing on oncology and inflammatory diseases, while also maximizing the value of its trusted dermatology, pain, respiratory and cardiovascular portfolio in countries around the world where there is still great need for these treatments. “The new Organon will carry forward this legacy by continuing to focus on meeting the unmet healthcare needs of women around the world.”įueled by its leading contraceptives and fertility businesses, Organon will invest in innovations that support the distinct health care needs of women today. “We chose a name that will instill trust and build on the strong legacy of Organon’s commitment to innovation in women’s health,” explained Kenneth C. The Organon name has strong brand equity and engenders great respect among health care professionals for its dedication and innovation in women’s health. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. KENILWORTH, N.J., Ma– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co.
0 kommentar(er)
